Marker Gene Technologies, Inc.

Marker Gene Technologies, Inc. has developed platform technologies that utilize transferred genes matched with new synthetic drug-analogs to alter the growth and biological characteristics of living cells in specific tissues of living organisms. These systems allow for the selective release of therapeutic drugs under the control of genetic processes within the cell. This proprietary system has shown promise in such varied applications as human gene therapy, plant biotechnology and industrial production of recombinant proteins.

Marker Gene Technologies’ primary focus is to use its proprietary Gene Therapy/Pro-Drug Delivery System to replace existing pharmaceutical protocols for the treatment of specific genetic diseases (cancer, cystic fibrosis, neurodegenerative diseases), especially those for which there are few proven alternative treatment regimens. The advantages of the MGT techniques are their ability to deliver high levels of drugs with reduced toxicity or side effects along with the capacity to administer a wider variety of drugs to a specific tissue or organ, using genetically controlled release.

While there is relatively broad competition in the area of cancer therapeutics, where the MGT technology has application, there are virtually no other competitors in this specialized industry niche. Marker Gene’s core technology is an enabling gene-based delivery system that addresses a variety of medical, agricultural and bio-industrial applications. Among the drugs currently under development are analogs of common chemotherapeutic agents, neuro-generative agents, vascularization- inhibition agents, immune-regulation agents, antibiotics, and herbicides. Allied programs in cancer diagnosis, apoptosis induction in cancer, cancer genomics and pharmacogenomics are underway.

MGT’s pioneering work in cancer therapeutics has been funded both privately, and through grants from the National Institutes of Health, The National Cancer Institute, The National Institute of General Medical Sciences, and The National Science Foundation.

For further information on Marker Gene Technologies, Inc. and the opportunities available in utilizing the company’s technology, please contact Michael P. Coughlin, Business Director, Dr. John J. Naleway, CEO or Dr. Anthony P. Guzikowski, Director of Chemistry at (541) 342-3760 and visit our Web site at http://www.markergene.com.